Financial Performance - The total revenue for the year ended December 31, 2022, was approximately HKD 1,851,532,000, representing a significant increase of over 197% compared to the previous year[8]. - Gross profit for the same period was approximately HKD 1,100,957,000, reflecting a year-on-year growth of 208%, with a gross margin of 59.46% (up from 57.40% in the previous year)[8]. - The company reported record revenue and profit during the fiscal year due to high demand for nucleic acid testing services amid the COVID-19 pandemic[48]. - The net profit attributable to the company's owners increased significantly to approximately HKD 258,087,000 in 2022 from HKD 19,385,000 in 2021, driven by high demand for COVID-19 testing services[175]. - Revenue from the medical laboratory testing and health check services increased from approximately HKD 607,776,000 in 2021 to approximately HKD 1,619,568,000 in 2022, representing a 166% increase[163]. COVID-19 Testing Services - The company completed over 10,000,000 COVID-19 nucleic acid tests during the year, an increase of over 183% compared to 3,600,000 tests completed in the previous year[13]. - The demand for medical laboratory testing services and health check services, including COVID-19 nucleic acid testing, remained high due to ongoing COVID-19 outbreaks[155]. - The company became one of the designated service providers for COVID-19 rapid nucleic acid testing at Shenzhen Bay Port and Hong Kong-Zhuhai-Macao Bridge Hong Kong Port for travelers leaving Hong Kong[155]. - The company provided over 15,000,000 COVID-19 nucleic acid tests during the pandemic, supporting the Hong Kong government's community testing initiatives[160]. Business Expansion and New Services - The company launched new medical laboratory testing and health check services, including pre-vaccination health checks and cancer screening tests, to enhance competitiveness in the post-pandemic era[14]. - The company has established six service agreements with regional health center operators to provide laboratory testing services for various diseases, including diabetes and colorectal cancer[15]. - A high-standard molecular biology laboratory has been established in collaboration with Pillar Biosciences, Inc. to enhance precision diagnostic testing services[15]. - The company aims to achieve further breakthroughs in business performance through the commercialization of a range of medical laboratory testing and healthcare services in the coming years[2]. - The company is focusing on restoring non-COVID-19 medical diagnostic and treatment services as the pandemic subsides[48]. Environmental Commitment - The company is committed to reducing its environmental footprint through sustainable practices in R&D, medical testing, and precision cancer diagnostics[73]. - The total greenhouse gas emissions related to the company's operations during the reporting period were estimated at 11,040 tons of CO2 equivalent, primarily due to increased business activities and higher electricity consumption[87]. - The company aims to reduce greenhouse gas emissions as part of its long-term environmental goals[126]. - The company has established an ESG committee to monitor progress and develop strategies to achieve ESG goals, recognizing the importance of ESG considerations for long-term success[73]. - The company has set policies to ensure compliance with all applicable environmental laws and regulations, fostering an environmentally conscious culture among employees[74]. Research and Development - Significant progress has been made in the research and development of immune cell therapy, with clinical trials for investigational new drugs currently underway[48]. - The company received approval for its investigational new drug (IND) application for LY007, a CAR-T therapy product, marking a significant milestone in its oncology treatment offerings[166]. - The company is seeking collaborations with contract research organizations and local hospitals for next-generation sequencing (NGS) cancer diagnostic tests[161]. Capital and Financing - The company issued convertible bonds totaling USD 10,000,000, equivalent to approximately HKD 77,800,000, with a conversion price of HKD 1.45 per share[125]. - The net proceeds from the convertible bonds are allocated as follows: HKD 23,340,000 for investment in boron neutron capture therapy projects and HKD 15,124,000 for R&D costs and general operating funds[125]. - The company entered a five-year exclusive distribution agreement for NMN products, allowing distribution rights in regions including Hong Kong, Macau, and several Southeast Asian countries[39]. Waste Management and Compliance - The group has established strict policies for the management of medical waste to ensure proper disposal[90]. - The company has implemented strict health and safety measures during the COVID-19 pandemic to ensure employee safety and minimize virus transmission[180]. - The company aims to maintain a zero-violation record in hazardous waste management, reflecting its commitment to compliance and safety standards[183]. - The company has not recorded any violations of environmental laws during the reporting period[128]. Employee and Operational Metrics - The total number of full-time employees was 260, with an overall turnover rate of 32% during the reporting period[140]. - The turnover rate for part-time employees was 18%, with 17 part-time employees reported[141]. - The employee turnover rate for males was 30% and for females was 31%[141]. - The turnover rate for employees under 30 years old was 35%, while it was 27% for those aged 30 to 50, and 31% for those over 50[141].
中国生物科技服务(08037) - 2022 - 年度财报